Stephen G Ellis

List of Publications by Year
in descending order

166	21,418	22153 59	8866 145
papers	citations	h-index	g-index

168	168	168	14267
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Feasibility of transradial primary percutaneous coronary intervention for <scp>STEMI</scp> complicated by cardiac arrest. Catheterization and Cardiovascular Interventions, 2022, 99, 1363-1365.	1.7	0
2	Outcomes of Interventional Management of Coronary Artery Disease in Kidney Transplant Recipients. Transplantation Proceedings, 2022, 54, 663-663.	0.6	1
3	Excimer Laser Atherectomy in Percutaneous Coronary Intervention: A Contemporary Review. Cardiovascular Revascularization Medicine, 2021, 25, 75-85.	0.8	29
4	Outcomes of Early Coronary Angiography or Revascularization After Cardiac Surgery. Annals of Thoracic Surgery, 2021, 111, 1494-1501.	1.3	8
5	Successful modeling of long term outcomes in endâ€stage renal disease patients undergoing percutaneous coronary intervention with drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, 208-214.	1.7	1
6	Implementation of a Myocardial Perfusion Imaging Risk Algorithm to Inform Appropriate Downstream Invasive Testing and Treatment. Circulation: Cardiovascular Imaging, 2021, 14, e011984.	2.6	5
7	Coronary Tortuosity and Long-Term Post-Stent Risk. JACC: Cardiovascular Interventions, 2021, 14, 1019-1020.	2.9	2
8	Prediabetic Patient Outcomes 8 to 15 Years After Drug-Eluting Coronary Stenting. American Journal of Cardiology, 2021, 149, 21-26.	1.6	0
9	Incidence, treatment, and outcomes of acute myocardial infarction following transcatheter or surgical aortic valve replacement. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	1
10	Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials. Journal of Cardiology, 2021, 78, 224-229.	1.9	2
11	Long-Term Outcomes of Patients With Mediastinal Radiationâ€"Associated Coronary Artery Disease Undergoing Coronary Revascularization With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. Circulation, 2020, 142, 1399-1401.	1.6	8
12	Endâ€stage renal disease as an independent risk factor for inâ€hospital mortality after coronary drugâ€eluting stenting: Understanding and modeling the risk. Catheterization and Cardiovascular Interventions, 2020, 98, 246-254.	1.7	1
13	Association of adoption of transradial access for percutaneous coronary intervention in ST elevation myocardial infarction with doorâ€toâ€balloon time. Catheterization and Cardiovascular Interventions, 2020, 96, E165-E173.	1.7	4
14	The role of ISCHEMIA in stable ischemic heart disease. Cleveland Clinic Journal of Medicine, 2020, 87, 401-409.	1.3	4
15	Utilization and outcomes of polytetrafluoroethylene covered stents in patients with coronary artery perforation and coronary artery aneurysm: Single center 15â€year experience. Catheterization and Cardiovascular Interventions, 2019, 94, 555-561.	1.7	9
16	CTO Coronary Perforations. JACC: Cardiovascular Interventions, 2019, 12, 1913-1914.	2.9	1
17	Comparison of Long-Term Clinical Outcomes After Drug-Eluting Stenting in Blacks-vs-Whites. American Journal of Cardiology, 2019, 124, 1179-1185.	1.6	3
18	Readmissions in ST-Elevation Myocardial Infarction and Cardiogenic Shock (from Nationwide) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 T	1.6	9

#	Article	IF	Citations
19	Angiographic predictors of adverse outcomes after percutaneous coronary intervention in patients with radiation associated coronary artery disease. Catheterization and Cardiovascular Interventions, 2019, 94, E104-E110.	1.7	4
20	Assessing the Likelihood of Chronic TotalÂOcclusion Percutaneous Coronary Intervention Procedural Success. JACC: Cardiovascular Interventions, 2019, 12, 343-345.	2.9	0
21	How Should We Treat Patients With Silent Myocardial Ischemia?. JACC: Cardiovascular Interventions, 2019, 12, 242-244.	2.9	1
22	Fractional flow reserve guided percutaneous coronary intervention results in reduced ischemic myocardium and improved outcomes. Catheterization and Cardiovascular Interventions, 2018, 92, 692-700.	1.7	3
23	Clinical, Angiographic, and ProceduralÂCorrelates of VeryÂLateÂAbsorbÂScaffoldÂThrombosis. JACC: Cardiovascular Interventions, 2018, 11, 638-644.	2.9	20
24	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2018, 39, 1726-1735a.	2.2	133
25	Operational Efficiency and Productivity Improvement Initiatives in a LargeÂCardiacÂCatheterization Laboratory. JACC: Cardiovascular Interventions, 2018, 11, 329-338.	2.9	10
26	4-Step Protocol for Disparities in STEMIÂCare and Outcomes in Women. Journal of the American College of Cardiology, 2018, 71, 2122-2132.	2.8	97
27	Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet, The, 2018, 392, 1530-1540.	13.7	103
28	Analysis of causal effect of APOA5 variants on premature coronary artery disease. Annals of Human Genetics, 2018, 82, 437-447.	0.8	8
29	Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2017, 89, E64-E74.	1.7	10
30	Bioresorbable Vascular Scaffolds. JACC: Cardiovascular Interventions, 2017, 10, 796-797.	2.9	0
31	Associations Between Cardiac Troponin, Mechanism of Myocardial Injury, and Longâ€Term Mortality After Noncardiac Vascular Surgery. Journal of the American Heart Association, 2017, 6, .	3.7	33
32	Predictors of Successful Hybrid-Approach Chronic Total Coronary Artery OcclusionÂStenting. JACC: Cardiovascular Interventions, 2017, 10, 1089-1098.	2.9	43
33	CLINICAL, ANGIOGRAPHIC AND PROCEDURAL CORRELATES OF ABSORB SCAFFOLD THROMBOSIS: A MATCHED MULTICENTER REGISTRY ANALYSIS. Journal of the American College of Cardiology, 2017, 69, 964.	2.8	1
34	Fantom Bioresorbable Scaffold. JACC: Cardiovascular Interventions, 2017, 10, 1839-1840.	2.9	2
35	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2017, 10, 1809-1815.	2.9	26
36	Recognized Obstructive Sleep Apnea is Associated With Improved Inâ€Hospital Outcomes After ST Elevation Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	3.7	29

#	Article	IF	Citations
37	Genome-Wide Linkage Analysis of Large Multiple Multigenerational Families Identifies Novel Genetic Loci for Coronary Artery Disease. Scientific Reports, 2017, 7, 5472.	3.3	12
38	Characteristics, Predictors, and Mechanisms of Thrombosis inÂCoronary Bioresorbable Scaffolds. JACC: Cardiovascular Interventions, 2017, 10, 2363-2371.	2.9	35
39	The State of the Absorb BioresorbableÂScaffold. JACC: Cardiovascular Interventions, 2017, 10, 2349-2359.	2.9	55
40	Prognostic Significance of Ischemic Mitral Regurgitation on Outcomes in Acute ST-Elevation Myocardial Infarction Managed by Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 119, 20-26.	1.6	25
41	Walking the right path: the story of bioresorbable stents. Journal of Thoracic Disease, 2017, 9, 1786-1788.	1.4	1
42	Unprotected Left Main Coronary Artery Disease: Management in the Post NOBLE and EXCEL Era. Interventional Cardiology Review, 2017, 12, 92.	1.6	1
43	Management of coronary chronic total occlusion. Cleveland Clinic Journal of Medicine, 2017, 84, 27-38.	1.3	7
44	Insights Into Timing, Risk Factors, and Outcomes of Stroke and Transient Ischemic Attack After Transcatheter Aortic Valve Replacement in the PARTNER Trial (Placement of Aortic Transcatheter) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	3.9	145
45	Percutaneous Intervention for Myocardial Infarction After Noncardiac Surgery. Journal of the American College of Cardiology, 2016, 68, 329-338.	2.8	42
46	Long-Term Mortality in Patients With Radiation-Associated Coronary Artery Disease Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	46
47	Frequency and factors associated with inappropriate for intervention cardiac catheterization laboratory activation. Cardiovascular Revascularization Medicine, 2016, 17, 219-224.	0.8	3
48	Management of drug eluting stent inâ€stent restenosis: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2016, 87, 1080-1091.	1.7	28
49	Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, e002453.	3.9	61
50	1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet, The, 2016, 387, 1277-1289.	13.7	253
51	Impact of lean six sigma process improvement methodology on cardiac catheterization laboratory efficiency. Cardiovascular Revascularization Medicine, 2016, 17, 95-101.	0.8	40
52	Utility of Glycated Hemoglobin for Assessment of Glucose Metabolism in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2016, 117, 749-753.	1.6	30
53	Bioresorbable stents: The future of interventional cardiology?. Cleveland Clinic Journal of Medicine, 2016, 83, S18-S23.	1.3	4
54	Length of stay and longâ€term mortality following <scp>ST</scp> elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2015, 86, S1-7.	1.7	15

#	Article	IF	Citations
55	Renin-Angiotensin System Antagonists in Patients Without Left Ventricular Dysfunction After Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 116, 508-514.	1.6	8
56	Role of Revascularization to Improve Left Ventricular Function. Heart Failure Clinics, 2015, 11, 203-214.	2.1	0
57	Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. New England Journal of Medicine, 2015, 373, 1905-1915.	27.0	554
58	Bioresorbable Stents: Is This Where We Are Headed?. Progress in Cardiovascular Diseases, 2015, 58, 342-355.	3.1	15
59	Do We Know the Best Treatment for In-Stent Restenosis Via Network Meta-Analysis (NMA)?. JACC: Cardiovascular Interventions, 2015, 8, 395-397.	2.9	1
60	Abstract 10954: Clinical and Angiographic Predictors of Adverse Outcomes After Percutaneous Coronary Intervention in Patients With Radiation Associated Coronary Artery Disease. Circulation, 2015, 132, .	1.6	0
61	Abstract 14566: Mild Elevation in Cardiac Troponin T is Independently Associated With Long-Term Mortality After Intermediate or High-Risk Vascular Surgery. Circulation, 2015, 132, .	1.6	0
62	Genome-Wide Linkage Scan Identifies Two Novel Genetic Loci for Coronary Artery Disease: In GeneQuest Families. PLoS ONE, 2014, 9, e113935.	2.5	8
63	Association of Glycemic Control With Mortality in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 503-509.	3.9	26
64	Prognostic Value of Estimated Functional Capacity Incremental to Cardiac Biomarkers in Stable Cardiac Patients. Journal of the American Heart Association, 2014, 3, e000960.	3.7	29
65	Influence of Transcatheter Aortic Valve Replacement Strategy and Valve Design onÂStroke After Transcatheter Aortic ValveÂReplacement. Journal of the American College of Cardiology, 2014, 63, 2101-2110.	2.8	123
66	High-Risk Coronary Atheroma. Journal of the American College of Cardiology, 2014, 63, 1134-1140.	2.8	32
67	Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction. Circulation Research, 2014, 115, 867-874.	4.5	65
68	Measures to Reduce Radiation in a Modern Cardiac Catheterization Laboratory. Circulation: Cardiovascular Interventions, 2014, 7, 447-455.	3.9	59
69	Survival Prediction Models for Coronary Intervention: Strategic Decision Support. Annals of Thoracic Surgery, 2014, 97, 522-528.	1.3	7
70	Presence of Diabetes Does Not Matter for Percutaneous Coronary Intervention Outcomes With Simple Coronary Lesions. Journal of the American College of Cardiology, 2014, 63, 2119-2120.	2.8	0
71	Abstract 17910: Patients with Newly Diagnosed Diabetes Have Comparable Long Term Mortality with Known Diabetics After ST Segment Elevation Myocardial Infarction. Circulation, 2014, 130, .	1.6	2
72	Abstract 16161: Bone Marrow Characteristics are Associated With Changes in Infarct Size Following STEMI: A Biorepository Evaluation From the CCTRN TIME Trial. Circulation, 2014, 130, .	1.6	1

#	Article	IF	Citations
73	Abstract 17075: Outcomes in Radiation Associated Cardiac Disease Patients that present with Coronary Artery Disease: Comparison between PCI and CABG. Circulation, 2014, 130, .	1.6	0
74	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	1.7	97
75	Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: A comparative study. Catheterization and Cardiovascular Interventions, 2013, 81, 294-300.	1.7	14
76	A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials. Current Atherosclerosis Reports, 2013, 15, 341.	4.8	8
77	Cause of Death Within 30 Days of Percutaneous Coronary Intervention in an Era of Mandatory Outcome Reporting. Journal of the American College of Cardiology, 2013, 62, 409-415.	2.8	56
78	Left Main Coronary Artery Stenosis. JACC: Cardiovascular Interventions, 2013, 6, 1219-1230.	2.9	101
79	Stent choice and the hidden consequences of cost savings. Nature Reviews Cardiology, 2012, 9, 559-560.	13.7	1
80	Safety of â€œBridgingâ€•With Eptifibatide for Patients With Coronary Stents Before Cardiac and Non-Cardiac Surgery. American Journal of Cardiology, 2012, 110, 485-490.	1.6	32
81	Eroding the Denominator. Journal of the American College of Cardiology, 2012, 60, 789-790.	2.8	9
82	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions, 2012, 79, 453-495.	1.7	157
83	Pilot Candidate Gene Analysis of Patients â‰¥60 Years Old With Aortic Stenosis Involving a Tricuspid Aortic Valve. American Journal of Cardiology, 2012, 110, 88-92.	1.6	16
84	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology, 2011, 58, 2550-2583.	2.8	114
85	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, e44-e122.	2.8	2,027
86	Enhanced Prediction of Mortality After Percutaneous Coronary Intervention by Consideration of General and Neurological Indicators. JACC: Cardiovascular Interventions, 2011, 4, 442-448.	2.9	21
87	Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 530-542.	2.9	57
88	Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function. JAMA - Journal of the American Medical Association, 2011, 306, 2110.	7.4	377
89	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Circulation, 2011, 124, 2574-2609.	1.6	500
90	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Circulation, 2011, 124, e574-651.	1.6	1,946

#	Article	IF	Citations
91	Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 203-212.	2.9	37
92	Drugâ€eluting stents versus bareâ€metal stents for treatment of bareâ€metal inâ€stent restenosis. Catheterization and Cardiovascular Interventions, 2010, 76, 257-262.	1.7	18
93	Percutaneous Left Main Invention. JACC: Cardiovascular Interventions, 2010, 3, 642-647.	2.9	2
94	Evaluation of Infarct-Related Coronary Artery Patency and Microcirculatory Function After Facilitated Percutaneous Primary Coronary Angioplasty. JACC: Cardiovascular Interventions, 2010, 3, 1284-1291.	2.9	29
95	The Weasel Clause: Excluding Patients From Door-to-Balloon Analyses. Journal of the American College of Cardiology, 2010, 56, 1763.	2.8	11
96	Characterization of Post-Operative Risk Associated With Prior Drug-Eluting Stent Use. JACC: Cardiovascular Interventions, 2009, 2, 542-549.	2.9	76
97	Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals. JACC: Cardiovascular Interventions, 2009, 2, 917-924.	2.9	76
98	1-Year Survival in a Randomized Trial of Facilitated Reperfusion. JACC: Cardiovascular Interventions, 2009, 2, 909-916.	2.9	59
99	Long-Term Safety and Efficacy With Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2009, 2, 1248-1259.	2.9	122
100	Drug-eluting versus bare-metal stents for treating saphenous vein grafts. American Heart Journal, 2009, 158, 637-643.	2.7	25
101	Comparison of Percutaneous Versus Surgical Revascularization of Severe Unprotected Left Main Coronary Stenosis in Matched Patients. American Journal of Cardiology, 2008, 101, 169-172.	1.6	96
102	Angiographic Surrogate End Points in Drug-Eluting Stent Trials. Journal of the American College of Cardiology, 2008, 51, 23-32.	2.8	153
103	Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus. Journal of the American College of Cardiology, 2008, 51, 708-715.	2.8	106
104	Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality. Journal of the American College of Cardiology, 2008, 52, 1041-1048.	2.8	41
105	Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. European Heart Journal, 2008, 29, 1625-1634.	2.2	54
106	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2205-2217.	27.0	596
107	Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation. Circulation, 2007, 115, 2842-2847.	1.6	162
108	A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2030-2036.	2.4	143

#	Article	IF	Citations
109	Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. New England Journal of Medicine, 2007, 356, 998-1008.	27.0	1,776
110	Incidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent. Journal of the American College of Cardiology, 2007, 49, 1043-1051.	2.8	121
111	â€œCrying Fire in a Theaterâ€•or a â€œConfirmatory Sighting?â€ âžâžEditorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology, 2007, 50, 268-269.	2.8	7
112	Relation of Polymorphisms in Five Genes to Long-Term Aortocoronary Saphenous Vein Graft Patency. American Journal of Cardiology, 2007, 99, 1087-1089.	1.6	15
113	Meta-Analysis of Angiographic Versus Intravascular Ultrasound Parameters of Drug-Eluting Stent Efficacy (from TAXUS IV, V, and VI). American Journal of Cardiology, 2007, 100, 621-626.	1.6	19
114	Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. Journal of Invasive Cardiology, 2007, 19, 404-9.	0.4	26
115	Restenosis, Statistics, and Reasonable Inferences. Journal of the American College of Cardiology, 2006, 47, 470-471.	2.8	2
116	Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents. Journal of the American College of Cardiology, 2006, 48, 32-36.	2.8	134
117	Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial. American Heart Journal, 2006, 152, 1051.e9-1051.e14.	2.7	63
118	Bare metal stent restenosis is not a benign clinical entity. American Heart Journal, 2006, 151, 1260-1264.	2.7	367
119	Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomyâ€”a propensity-adjusted analysis. American Heart Journal, 2006, 151, 1031.e1-1031.e6.	2.7	6
120	Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2006, 67, 541-545.	1.7	151
121	Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents. JAMA - Journal of the American Medical Association, 2006, 295, 1253.	7.4	243
122	Impact of Platelet Glycoprotein IIb/IIIa Inhibition on the Paclitaxel-Eluting Stent in Patients With Stable or Unstable Angina Pectoris or Provocable Myocardial Ischemia (A TAXUS IV Substudy). American Journal of Cardiology, 2005, 96, 500-505.	1.6	11
123	Identification of Four Gene Variants Associated with Myocardial Infarction. American Journal of Human Genetics, 2005, 77, 596-605.	6.2	142
124	LightTyperâ„¢ platform for high-throughput clinical genotyping. Expert Review of Molecular Diagnostics, 2005, 5, 457-471.	3.1	10
125	The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention. American Heart Journal, 2005, 150, 1190-1197.	2.7	17
126	Creation of a large-scale genetic data bank for cardiovascular association studies. American Heart Journal, 2005, 150, 500-506.	2.7	6

#	Article	IF	Citations
127	Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation. Journal of the American College of Cardiology, 2005, 45, 1201-1205.	2.8	88
128	Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation. Journal of the American College of Cardiology, 2005, 45, 1193-1200.	2.8	149
129	A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. New England Journal of Medicine, 2004, 350, 221-231.	27.0	2,601
130	Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 2004, 93, 679-684.	1.6	117
131	Effects of long-term prednisone (â‰¥5 mg) use on outcomes and complications of percutaneous coronary intervention. American Journal of Cardiology, 2004, 93, 1389-1390.	1.6	15
132	Real-world bare metal stenting: Identification of patients at low or very low risk of 9-month coronary revascularization. Catheterization and Cardiovascular Interventions, 2004, 63, 135-140.	1.7	33
133	First human randomized trial of G-CSF stem cell mobilization to treat large acute myocardial infarctionâ€"preliminary results of a pilot study. International Congress Series, 2004, 1262, 364-367.	0.2	1
134	Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) trial. American Heart Journal, 2004, 147, 684.	2.7	88
135	GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention. American Heart Journal, 2004, 148, 1003-1006.	2.7	3
136	Plaque that makes a patient vulnerable. Journal of Invasive Cardiology, 2004, 16, 401.	0.4	0
137	Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet, The, 2003, 362, 697-703.	13.7	1,199
138	Death Following Creatine Kinase-MB Elevation After Coronary Intervention. Circulation, 2002, 106, 1205-1210.	1.6	204
139	Emergency Coronary Artery Bypass Surgery in the Contemporary Percutaneous Coronary Intervention Era. Circulation, 2002, 106, 2346-2350.	1.6	195
140	Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. Journal of the American College of Cardiology, 2002, 40, 669-675.	2.8	34
141	Impact of mitral regurgitation on long-term survival after percutaneous coronary intervention. American Journal of Cardiology, 2002, 89, 315-318.	1.6	122
142	Comparison of long-term survival following nonâ€"Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated. American Journal of Cardiology, 2002, 89, 751-753.	1.6	4
143	Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting. American Journal of Cardiology, 2002, 89, 937-940.	1.6	35
144	Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. American Journal of Cardiology, 2002, 89, 1209-1211.	1.6	28

#	Article	IF	Citations
145	Incremental progress? The roles of direct stenting and routine troponin measurement after percutaneous coronary intervention. Journal of Invasive Cardiology, 2002, 14, 171-2.	0.4	0
146	Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention. Circulation, 2001, 104, 992-997.	1.6	241
147	Î²-Blockers Before Percutaneous Coronary Intervention Do Not Attenuate Postprocedural Creatine Kinase Isoenzyme Rise. Circulation, 2001, 104, 2685-2688.	1.6	36
148	Long-Term Clinical Outcomes After Unprotected Left Main Trunk Percutaneous Revascularization in 279 Patients. Circulation, 2001, 104, 1609-1614.	1.6	217
149	Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting. New England Journal of Medicine, 2001, 344, 250-256.	27.0	608
150	Immediate sealing of arterial puncture sites after cardiac catheterization and coronary interventions: Initial U.S. feasibility trial using the Duett vascular closure device. Catheterization and Cardiovascular Interventions, 2000, 50, 96-102.	1.7	32
151	Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. American Journal of Cardiology, 2000, 86, 780-782.	1.6	93
152	Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions. Circulation, 2000, 102, 28-34.	1.6	69
153	Relation Between Lesion Characteristics and Risk With Percutaneous Intervention in the Stent and Glycoprotein IIb/IIIa Era. Circulation, 1999, 100, 1971-1976.	1.6	88
154	Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction. Circulation, 1999, 100, 14-20.	1.6	532
155	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. , 1997, 42, 102-108.		13
156	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. Catheterization and Cardiovascular Diagnosis, 1997, 42, 102-108.	0.3	1
157	Contemporary Percutaneous Treatment of Unprotected Left Main Coronary Stenoses. Circulation, 1997, 96, 3867-3872.	1.6	182
158	Low-Normal or Excessive Body Mass Index: Newly Identified and Powerful Risk Factors for Death and Other Complications With Percutaneous Coronary Intervention. American Journal of Cardiology, 1996, 78, 642-646.	1.6	130
159	Analysis and Comparison of Operator-Specific Outcomes in Interventional Cardiology. Circulation, 1996, 93, 431-439.	1.6	66
160	Significance of Mild Transient Release of Creatine Kinaseâ€“MB Fraction After Percutaneous Coronary Interventions. Circulation, 1996, 94, 1528-1536.	1.6	305
161	Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries. Circulation, 1996, 94, 1690-1697.	1.6	726
162	Reduction in Myocardial Infarct Size by Basic Fibroblast Growth Factor After Temporary Coronary Occlusion in a Canine Model. Circulation, 1996, 94, 1927-1933.	1.6	57

#	Article	IF	Citations
163	Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S. Palmaz-Schatz stent experience. Journal of the American College of Cardiology, 1995, 26, 704-712.	2.8	161
164	Long-term Outcome of Transient, Uncomplicated In-Laboratory Coronary Artery Closure. Circulation, 1995, 91, 2733-2741.	1.6	60
165	Comparison of three coronary stents: Clinical and angiographic outcome after elective placement in 134 consecutive patients. Catheterization and Cardiovascular Diagnosis, 1994, 33, 199-204.	0.3	21
166	Is traditionally defined complete revascularization needed for patients with multivessel disease treated by elective coronary angioplasty?. Journal of the American College of Cardiology, 1993, 22, 1289-1297.	2.8	58